- Home
- VYGR vs ELVR Comparison
VYGR vs ELVR Comparison
Compare VYGR & ELVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- ELVR
- Stock Information
- Founded
- VYGR 2013
- ELVR 2000
- Country
- VYGR United States
- ELVR Australia
- Employees
- VYGR N/A
- ELVR N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- ELVR Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- VYGR Health Care
- ELVR Industrials
- Exchange
- VYGR Nasdaq
- ELVR Nasdaq
- Market Cap
- VYGR 231.9M
- ELVR 254.1M
- IPO Year
- VYGR 2015
- ELVR N/A
- Fundamental
- Price
- VYGR $4.23
- ELVR $24.65
- Analyst Decision
- VYGR Strong Buy
- ELVR
- Analyst Count
- VYGR 7
- ELVR 0
- Target Price
- VYGR $17.00
- ELVR N/A
- AVG Volume (30 Days)
- VYGR 551.0K
- ELVR 98.5K
- Earning Date
- VYGR 11-06-2025
- ELVR 10-29-2025
- Dividend Yield
- VYGR N/A
- ELVR N/A
- EPS Growth
- VYGR N/A
- ELVR N/A
- EPS
- VYGR N/A
- ELVR N/A
- Revenue
- VYGR $42,580,000.00
- ELVR $146,440,045.00
- Revenue This Year
- VYGR N/A
- ELVR $9.75
- Revenue Next Year
- VYGR $107.10
- ELVR $8.82
- P/E Ratio
- VYGR N/A
- ELVR N/A
- Revenue Growth
- VYGR N/A
- ELVR 11.20
- 52 Week Low
- VYGR $2.65
- ELVR $15.55
- 52 Week High
- VYGR $7.44
- ELVR $33.36
- Technical
- Relative Strength Index (RSI)
- VYGR 41.58
- ELVR N/A
- Support Level
- VYGR $4.10
- ELVR N/A
- Resistance Level
- VYGR $4.30
- ELVR N/A
- Average True Range (ATR)
- VYGR 0.26
- ELVR 0.00
- MACD
- VYGR -0.10
- ELVR 0.00
- Stochastic Oscillator
- VYGR 20.89
- ELVR 0.00
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.